Abcellera Historical Balance Sheet

ABCL Stock

USD 2.42 0.11 4.35%

Trend analysis of Abcellera Biologics balance sheet accounts such as Short Long Term Debt Total of 42.9 M, Other Current Liabilities of 47.7 M or Total Current Liabilities of 86.8 M provides information on Abcellera Biologics' total assets, liabilities, and equity, which is the actual value of Abcellera Biologics to its prevalent stockholders. By breaking down trends over time using Abcellera Biologics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Abcellera Biologics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Abcellera Biologics is a good buy for the upcoming year.

Abcellera Biologics Inventory

1.29 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

About Abcellera Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Abcellera Biologics at a specified time, usually calculated after every quarter, six months, or one year. Abcellera Biologics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Abcellera Biologics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Abcellera currently owns. An asset can also be divided into two categories, current and non-current.

Abcellera Biologics Balance Sheet Chart

At this time, Abcellera Biologics' Cash is quite stable compared to the past year. Common Stock Shares Outstanding is expected to rise to about 295.1 M this year, although the value of Short and Long Term Debt Total will most likely fall to about 42.9 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Abcellera Biologics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Abcellera Biologics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Abcellera Biologics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Abcellera Biologics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Abcellera Biologics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Abcellera Biologics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.At this time, Abcellera Biologics' Cash is quite stable compared to the past year. Common Stock Shares Outstanding is expected to rise to about 295.1 M this year, although the value of Short and Long Term Debt Total will most likely fall to about 42.9 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	82.3M	77.4M	60.7M	42.9M
Total Assets	1.5B	1.5B	1.4B	1.1B

Short Long Term Debt Total Total Assets

Abcellera Biologics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		0.9	0.95	0.98	1.0	0.98	0.96	0.83	0.91	-0.65	0.92	0.89	0.77	0.97	0.96	0.99	0.61	0.98	0.84	0.98	0.8	0.65	1.0	1.0	0.82	-0.98
Short Long Term Debt Total	0.9		0.81	0.82	0.9	0.88	0.88	0.88	0.98	-0.31	0.9	0.81	0.47	0.96	0.81	0.88	0.24	0.83	0.74	0.95	0.87	0.67	0.92	0.9	0.88	-0.82
Other Current Liab	0.95	0.81		0.99	0.95	0.91	0.87	0.67	0.84	-0.75	0.95	0.78	0.85	0.85	0.88	0.97	0.71	0.91	0.82	0.94	0.66	0.45	0.93	0.95	0.67	-0.93
Total Current Liabilities	0.98	0.82	0.99		0.98	0.94	0.92	0.73	0.85	-0.76	0.92	0.82	0.86	0.9	0.93	0.99	0.73	0.96	0.82	0.95	0.7	0.53	0.96	0.98	0.72	-0.98
Total Stockholder Equity	1.0	0.9	0.95	0.98		0.97	0.96	0.82	0.91	-0.66	0.92	0.88	0.79	0.96	0.96	1.0	0.62	0.98	0.84	0.97	0.8	0.64	0.99	1.0	0.82	-0.98
Other Liab	0.98	0.88	0.91	0.94	0.97		0.93	0.8	0.85	-0.63	0.88	0.95	0.74	0.96	0.95	0.96	0.6	0.97	0.84	0.97	0.76	0.64	0.99	0.97	0.8	-0.95
Net Tangible Assets	0.96	0.88	0.87	0.92	0.96	0.93		0.93	0.88	-0.54	0.84	0.88	0.71	0.95	0.9	0.95	0.5	0.94	0.82	0.93	0.89	0.82	0.96	0.96	0.93	-0.97
Property Plant And Equipment Net	0.83	0.88	0.67	0.73	0.82	0.8	0.93		0.85	-0.19	0.71	0.83	0.4	0.91	0.74	0.79	0.17	0.77	0.69	0.85	0.94	0.94	0.85	0.82	1.0	-0.81
Current Deferred Revenue	0.91	0.98	0.84	0.85	0.91	0.85	0.88	0.85		-0.39	0.92	0.73	0.54	0.93	0.82	0.9	0.3	0.85	0.72	0.93	0.87	0.63	0.91	0.91	0.84	-0.84
Net Debt	-0.65	-0.31	-0.75	-0.76	-0.66	-0.63	-0.54	-0.19	-0.39		-0.6	-0.45	-0.97	-0.44	-0.7	-0.7	-0.94	-0.72	-0.58	-0.53	-0.25	-0.07	-0.59	-0.67	-0.18	0.71
Retained Earnings	0.92	0.9	0.95	0.92	0.92	0.88	0.84	0.71	0.92	-0.6		0.73	0.72	0.86	0.81	0.94	0.49	0.85	0.81	0.94	0.76	0.46	0.91	0.92	0.7	-0.86
Accounts Payable	0.89	0.81	0.78	0.82	0.88	0.95	0.88	0.83	0.73	-0.45	0.73		0.57	0.92	0.87	0.85	0.48	0.89	0.77	0.9	0.72	0.73	0.92	0.88	0.83	-0.86
Cash	0.77	0.47	0.85	0.86	0.79	0.74	0.71	0.4	0.54	-0.97	0.72	0.57		0.59	0.78	0.82	0.9	0.81	0.69	0.67	0.45	0.28	0.72	0.79	0.39	-0.84
Non Current Assets Total	0.97	0.96	0.85	0.9	0.96	0.96	0.95	0.91	0.93	-0.44	0.86	0.92	0.59		0.92	0.94	0.42	0.94	0.79	0.97	0.85	0.74	0.98	0.96	0.9	-0.92
Long Term Debt	0.96	0.81	0.88	0.93	0.96	0.95	0.9	0.74	0.82	-0.7	0.81	0.87	0.78	0.92		0.94	0.68	0.98	0.7	0.9	0.71	0.6	0.95	0.96	0.74	-0.95
Cash And Short Term Investments	0.99	0.88	0.97	0.99	1.0	0.96	0.95	0.79	0.9	-0.7	0.94	0.85	0.82	0.94	0.94		0.65	0.98	0.84	0.97	0.78	0.6	0.98	1.0	0.78	-0.98
Net Receivables	0.61	0.24	0.71	0.73	0.62	0.6	0.5	0.17	0.3	-0.94	0.49	0.48	0.9	0.42	0.68	0.65		0.7	0.51	0.51	0.11	0.06	0.57	0.62	0.16	-0.69
Common Stock Total Equity	0.98	0.83	0.91	0.96	0.98	0.97	0.94	0.77	0.85	-0.72	0.85	0.89	0.81	0.94	0.98	0.98	0.7		0.81	0.93	0.74	0.62	0.97	0.98	0.77	-0.98
Common Stock Shares Outstanding	0.84	0.74	0.82	0.82	0.84	0.84	0.82	0.69	0.72	-0.58	0.81	0.77	0.69	0.79	0.7	0.84	0.51	0.81		0.83	0.7	0.56	0.84	0.84	0.69	-0.82
Non Current Liabilities Total	0.98	0.95	0.94	0.95	0.97	0.97	0.93	0.85	0.93	-0.53	0.94	0.9	0.67	0.97	0.9	0.97	0.51	0.93	0.83		0.79	0.64	0.99	0.97	0.84	-0.93
Other Current Assets	0.8	0.87	0.66	0.7	0.8	0.76	0.89	0.94	0.87	-0.25	0.76	0.72	0.45	0.85	0.71	0.78	0.11	0.74	0.7	0.79		0.87	0.81	0.8	0.93	-0.78
Other Stockholder Equity	0.65	0.67	0.45	0.53	0.64	0.64	0.82	0.94	0.63	-0.07	0.46	0.73	0.28	0.74	0.6	0.6	0.06	0.62	0.56	0.64	0.87		0.68	0.64	0.94	-0.68
Total Liab	1.0	0.92	0.93	0.96	0.99	0.99	0.96	0.85	0.91	-0.59	0.91	0.92	0.72	0.98	0.95	0.98	0.57	0.97	0.84	0.99	0.81	0.68		0.99	0.85	-0.97
Net Invested Capital	1.0	0.9	0.95	0.98	1.0	0.97	0.96	0.82	0.91	-0.67	0.92	0.88	0.79	0.96	0.96	1.0	0.62	0.98	0.84	0.97	0.8	0.64	0.99		0.82	-0.98
Property Plant And Equipment Gross	0.82	0.88	0.67	0.72	0.82	0.8	0.93	1.0	0.84	-0.18	0.7	0.83	0.39	0.9	0.74	0.78	0.16	0.77	0.69	0.84	0.93	0.94	0.85	0.82		-0.81
Short Long Term Debt	-0.98	-0.82	-0.93	-0.98	-0.98	-0.95	-0.97	-0.81	-0.84	0.71	-0.86	-0.86	-0.84	-0.92	-0.95	-0.98	-0.69	-0.98	-0.82	-0.93	-0.78	-0.68	-0.97	-0.98	-0.81

Click cells to compare fundamentals

Abcellera Biologics Account Relationship Matchups

Abcellera Biologics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.0B	1.3B	1.5B	1.5B	1.4B	1.1B
Short Long Term Debt Total	6.1M	36.4M	82.3M	77.4M	60.7M	42.9M
Other Current Liab	52.6M	77.5M	76.3M	68.4M	28.7M	47.7M
Total Current Liabilities	103.5M	120.7M	118.3M	119.0M	76.6M	86.8M
Total Stockholder Equity	830.5M	1.0B	1.2B	1.2B	1.1B	836.0M
Other Liab	1.3M	65.6M	134.0M	112.6M	129.5M	69.6M
Net Tangible Assets	2.7M	683.9M	829.5M	1.1B	1.2B	1.3B
Property Plant And Equipment Net	17.9M	111.6M	217.3M	287.7M	340.4M	357.5M
Current Deferred Revenue	6.6M	7.5M	21.6M	19.0M	13.5M	11.6M
Net Debt	(588.0M)	(439.7M)	(304.3M)	(55.9M)	(95.6M)	(100.4M)
Retained Earnings	114.2M	267.7M	426.2M	279.8M	116.9M	188.2M
Accounts Payable	7.3M	32.0M	14.8M	25.5M	34.4M	18.4M
Cash	594.1M	476.1M	386.5M	133.3M	156.3M	277.3M
Non Current Assets Total	192.2M	388.8M	515.4M	616.1M	609.2M	367.5M
Cash And Short Term Investments	594.1M	723.0M	886.5M	760.6M	625.6M	566.9M
Net Receivables	213.2M	160.6M	38.6M	64.4M	33.6M	31.9M
Common Stock Total Equity	5.1M	710.4M	722.4M	734.4M	844.5M	479.0M
Common Stock Shares Outstanding	269.5M	318.3M	314.8M	289.2M	294.3M	295.1M
Liabilities And Stockholders Equity	1.0B	1.3B	1.5B	1.5B	1.4B	1.1B
Non Current Liabilities Total	71.5M	172.2M	189.3M	216.8M	151.2M	127.3M
Capital Lease Obligations	3.7M	36.4M	82.3M	77.4M	65.4M	42.1M
Other Current Assets	4.6M	21.2M	98.9M	45.9M	92.1M	96.7M
Other Stockholder Equity	5.9M	35.4M	74.1M	121.1M	283.3M	297.5M
Total Liab	175.0M	292.8M	307.6M	335.8M	304.5M	226.1M
Net Invested Capital	832.9M	1.0B	1.2B	1.2B	1.1B	835.1M
Property Plant And Equipment Gross	17.9M	121.4M	235.7M	318.3M	380.1M	399.2M
Total Current Assets	813.3M	929.8M	1.0B	872.0M	751.4M	694.5M
Capital Stock	710.4M	722.4M	734.4M	753.2M	777.2M	585.0M
Net Working Capital	709.8M	809.1M	907.2M	753.0M	674.8M	607.7M
Short Term Debt	865K	3.7M	5.6M	6.2M	7.1M	4.0M
Common Stock	710.4M	722.4M	734.4M	753.2M	777.2M	582.6M
Property Plant Equipment	8.5M	17.9M	111.6M	217.3M	249.8M	262.3M
Non Currrent Assets Other	2.5M	23.2M	41.0M	94.2M	96.5M	101.4M
Inventory	1.4M	1.7M	1.5M	1.1M	1.3M	1.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports:

How To Invest In Abcellera

Details

Is Abcellera Stock a good investment?

Details

What is Abcellera Biologics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.459

Earnings Share

(0.55)

Revenue Per Share

0.098

Quarterly Revenue Growth

(0.45)

Return On Assets

(0.12)

The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Abcellera Historical Balance Sheet

Abcellera Biologics Inventory

1.29 Million

About Abcellera Balance Sheet Analysis

Abcellera Biologics Balance Sheet Chart

Total Assets

Total Current Liabilities

Abcellera Biologics balance sheet Correlations

Abcellera Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Abcellera Biologics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Short Long Term Debt	- 0.98	Net Invested Capital
Short Long Term Debt	- 0.98	Common Stock Total Equity
Short Long Term Debt	- 0.98	Cash And Short Term Investments
Short Long Term Debt	- 0.98	Total Stockholder Equity
Short Long Term Debt	- 0.98	Total Current Liabilities
Short Long Term Debt	- 0.98	Total Assets